Agenda
Friday, November 30, 2018

Prostate Brachytherapy

7:00 am  Registration and Continental Breakfast
8:00   Welcome
       Albert Koong, MD
8:05   Bending the Slope of the Brachytherapy Curve
       Clinical Management – New Brachytherapy Data
       Steven J. Frank, MD

Clinical Management - New Brachytherapy Data

8:15   Unfavorable High-Risk Disease
       Juanita M. Crook, MD, FRCPC
8:25   Favorable High-Risk Disease
       Richard G. Stock, MD
8:35   Unfavorable Intermediate-Risk Disease and Update on Ascende RT Trial
       Mira M. Keyes, MD, FRCPC
8:45   Favorable Intermediate-Risk Disease and Update on RTOG 0232
       Bradley R. Prestidge, MD, MS
8:55   MD Anderson Phase II Trial of Monotherapy for Intermediate Risk Localized Disease
       Thomas J. Pugh, MD
9:05   Focal Brachytherapy - When, How, and Why?
       Michael J. Zelefsky, MD
9:15   Panel Discussion
9:45   Break

MRI-Assisted Radiosurgery (MARS) for HDR and LDR Brachytherapy

10:00  MRI of the Prostate - Screening, Diagnosis, and Surveillance Setting
       Tharakeswara K. Bathala, MD
10:10  MRI of the Prostate for the Brachytherapist
       Patrick W. McLaughlin, MD
10:20  MARS for LDR Brachytherapy
       Steven J. Frank, MD
10:30  MARS for HDR Brachytherapy
       Cynthia M. Menard, MD
10:40  MRI-based Treatment Planning Systems and QA-LDR
       Rajat J. Kudchadker, PhD
10:50  MRI-based Treatment Planning Systems and QA-HDR
       Firas M. Mourtada, PhD
11:00  Optimizing MRI Sequences for Brachytherapy
       Jingfei M. Ma, PhD
11:10  Panel Discussion
11:45  Break
12:00 pm  Lunch - Keynote Speaker
Improving Prostate Brachytherapy Access for Veterans
Michael P. Hagan, MD, PhD
1:00  Brachytherapy for the VA Patient-The Process of Optimizing Care
Jeffery A. Jones, MD
1:20  Immunotherapy and Brachytherapy-Defining an Abscopal Effect
Chandan M. Guha, MD, PhD
1:30  Redefining the Brachytherapy Definition of Failure
Howard Thames, PhD
1:40  Management for Rising PSA Following Radiation Treatment
Michael M. Ghilezan, MD, PhD
1:50  Prostate Imaging During the Recurrent Setting
Aradhana M. Venkatesan, MD
2:00  Sexual Outcomes Data and Management
Pierre M. Blanchard, MD PhD
2:10  Optimizing Sexual Function After Brachytherapy
Run Wang, MD
2:20  Urinary Outcomes Data and Management
William Graber, MD
2:30  Rectal Outcome Data and Management
Mitchell S. Anscher, MD
2:40  The Use of Hydrogel Spacer in Brachytherapy: LDR, HDR Monotherapy, or Combination Treatment with IMRT or Protons
Brian J. Davis, MD PhD
2:50  Panel Discussion
3:20  Break

Building a Brachytherapy Practice
3:30  The Road to LDR Brachytherapy Clinical Proficiency
Chad M. Tang, MD
3:40  The Road to HDR Brachytherapy Clinical Proficiency
Anna M. Likhacheva, MD, MPH
3:50  Essentials for Growing an LDR Practice
John E. Sylvester, MD
4:00  Essentials for Growing an HDR Practice
Peter J. Rossi, MD
4:10  Communicating Value in Prostate Brachytherapy
Nikhil G. Thaker, MD
4:20  Brachytherapy Advocacy and Payment Models
Peter F. Orio, III, DO, MS
4:30  What Defines a Medical Event in Brachytherapy
Zoubir Ouhib, PhD
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping, and videotaping are prohibited.